bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: S A J J M A M F J
2018: D N O S

 
  Other news for:
Lupus
 Resources from HONselect
Benlysta Approved for Children With Lupus

By Scott Roberts

MONDAY, April 29, 2019 (HealthDay News) -- The intravenous drug Benlysta (belimumab) has been approved by the U.S. Food and Drug Administration to treat children with lupus, a chronic disease that triggers inflammation and damages tissues and organs throughout the body.

Approved for adults since 2011, Benlysta is the first lupus treatment in the United States approved for children, the agency said in a news release.

"While there is no cure for lupus, treatment can help our youngest patients control their disease with the hope of improving their quality of life and lowering their risk of long-term organ damage and disability," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Though rare, childhood lupus typically is more serious than is lupus among adults. Children are at higher risk for developing serious organ damage and other complications, the FDA said.

Benlysta was clinically evaluated among 93 children with the disease. Those who received Benlysta plus standard therapy had a lower risk of a severe flare, the agency said.

The drug's label includes warnings for increased risk of death, serious infections, allergic-like reactions and depression. The drug should not be given at the same time as a person gets a live vaccine, the agency warned.

The drug's most common side effects include nausea, diarrhea and fever. Given the medication's history for causing allergic-like reactions, health professionals are advised to pre-treat users with an antihistamine, the FDA said.

Benlysta is produced by GlaxoSmithKline, based in the United Kingdom.

More information

Visit the FDA to learn more.

Copyright © 2019 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=745637

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Risk
Adult
Therapeutics
Infection
Fever
Tissues
Chronic Disease
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact